- Home
- IVVD vs OPAD Comparison
IVVD vs OPAD Comparison
Compare IVVD & OPAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- OPAD
- Stock Information
- Founded
- IVVD 2020
- OPAD 2015
- Country
- IVVD United States
- OPAD United States
- Employees
- IVVD N/A
- OPAD N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- OPAD Real Estate
- Sector
- IVVD Health Care
- OPAD Finance
- Exchange
- IVVD Nasdaq
- OPAD Nasdaq
- Market Cap
- IVVD 116.8M
- OPAD 99.9M
- IPO Year
- IVVD 2021
- OPAD N/A
- Fundamental
- Price
- IVVD $0.70
- OPAD $3.84
- Analyst Decision
- IVVD Strong Buy
- OPAD Hold
- Analyst Count
- IVVD 5
- OPAD 5
- Target Price
- IVVD $7.11
- OPAD $5.33
- AVG Volume (30 Days)
- IVVD 581.2K
- OPAD 37.7K
- Earning Date
- IVVD 11-14-2024
- OPAD 11-04-2024
- Dividend Yield
- IVVD N/A
- OPAD N/A
- EPS Growth
- IVVD N/A
- OPAD N/A
- EPS
- IVVD N/A
- OPAD N/A
- Revenue
- IVVD $11,564,000.00
- OPAD $985,005,000.00
- Revenue This Year
- IVVD N/A
- OPAD N/A
- Revenue Next Year
- IVVD $72.22
- OPAD $37.39
- P/E Ratio
- IVVD N/A
- OPAD N/A
- Revenue Growth
- IVVD N/A
- OPAD N/A
- 52 Week Low
- IVVD $0.71
- OPAD $2.57
- 52 Week High
- IVVD $5.20
- OPAD $11.22
- Technical
- Relative Strength Index (RSI)
- IVVD 33.40
- OPAD 56.75
- Support Level
- IVVD $0.72
- OPAD $3.50
- Resistance Level
- IVVD $0.81
- OPAD $3.94
- Average True Range (ATR)
- IVVD 0.07
- OPAD 0.38
- MACD
- IVVD -0.02
- OPAD 0.02
- Stochastic Oscillator
- IVVD 1.12
- OPAD 45.52
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.